Medicinova Inc (MNOV)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Yuichi Iwaki
Employees:
10
4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CA, 92037
858-373-1500
MediciNova, Inc. focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders. MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the. treatment of acute exacerbations of asthma, MN-001 (tipelukast) is an orally bioavailable small molecule compound to treat fibrotic diseases.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|